Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy

View source ↗

Summary

The EMA announces the withdrawal of Xigris (drotrecogin alfa activated) from the market due to lack of efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• Xigris (Drotrecogin alfa (activated))